{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-dyspnoea/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"83260a2e-73f3-5abd-b049-c307d85d2cff","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field a7b661e8-067c-4f9a-9308-26ad58033aeb --><h2>Changes</h2><!-- end field a7b661e8-067c-4f9a-9308-26ad58033aeb -->","summary":null,"htmlStringContent":"<!-- begin item 7c635324-9080-4f7d-a6c6-9095503432d2 --><!-- begin field 4eee94ec-6df7-4dd1-afde-48f1b99ea999 --><p><strong>November 2020 </strong>— minor update. Sleep apnoea syndrome added as an adverse effect of opioids.</p><p><strong>April 2020 </strong>— minor update. New management scenario created to provide information regarding COVID-19. </p><p><strong>July 2015 to October 2016</strong> — reviewed. Literature searches were conducted in September 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. There have been structural changes to the topic and changes to the recommendations have been updated in line with NICE guidance <em>Care of dying adults in the last days of life </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">NICE, 2015a</a>]. </p><!-- end field 4eee94ec-6df7-4dd1-afde-48f1b99ea999 --><!-- end item 7c635324-9080-4f7d-a6c6-9095503432d2 -->","topic":{"id":"20d4363b-caf3-55a9-beed-09266efa45f4","topicId":"73af552e-909d-456c-86d1-11f7a65040d8","topicName":"Palliative care - dyspnoea","slug":"palliative-care-dyspnoea","lastRevised":"Last revised in November 2020","chapters":[{"id":"0614f3a6-7238-5427-b059-9195b0cc2aa1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738e7584-0909-59c3-bd54-43100aed01fe","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ea721a0d-cda2-5620-8e3f-61e76920b9b3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"83260a2e-73f3-5abd-b049-c307d85d2cff","slug":"changes","fullItemName":"Changes"},{"id":"460710fb-be39-5a74-8adf-44beac90510f","slug":"update","fullItemName":"Update"}]},{"id":"a2422ca0-3b24-5c6e-81d8-07d257fdd44a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2753bf62-a22c-5fb2-936c-554ef07426d4","slug":"goals","fullItemName":"Goals"},{"id":"65f25469-16d4-5c7f-b7bc-a6698ca61164","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"52a827c5-48de-5c0c-8dce-6c7eeeab720d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"cd3e39be-06ce-5750-a1f7-cbc06bb58756","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"50c51a08-6607-5699-96a8-d66cb532d2c5","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"05dc5599-43b4-5340-841b-3b3208f4b947","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1fd04fd1-0023-5c48-9785-d9a54c7e2eb0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a84982b-be4e-5901-a577-110f09001119","slug":"definition","fullItemName":"Definition"},{"id":"dab82422-38f4-5a30-b0db-ad2cbf33c2ab","slug":"prevalence-of-dyspnoea-in-palliative-care","fullItemName":"Prevalence of dyspnoea in palliative care"},{"id":"ea086054-ae8f-5666-9159-99b04676d230","slug":"causes-of-dyspnoea","fullItemName":"Causes of dyspnoea"},{"id":"c2601cd4-69b1-563f-870a-8110f4c24103","slug":"complications-of-dyspnoea","fullItemName":"Complications of dyspnoea"}]},{"id":"db288340-b73c-59b1-a8ba-4baec577b887","fullItemName":"Management","slug":"management","subChapters":[{"id":"62ed0387-08f9-5656-8079-a5fffee537f4","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"cdb4ccb3-9b96-5651-9950-6e2e0b8f4da0","slug":"symptomatic-treatment","fullItemName":"Scenario: Symptomatic treatment"},{"id":"5b9d65e3-1fc3-558d-a95e-5e4ff147c7d7","slug":"known-cause-of-dyspnoea","fullItemName":"Scenario: Known cause of dyspnoea"},{"id":"3b6b57e5-ba14-5311-bbf3-d996401c7dc6","slug":"end-of-life-care","fullItemName":"Scenario: End of life care"},{"id":"9983f052-047c-5346-adfc-b741909ce269","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"08f118cb-d39f-532d-b39f-fa97739c656d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"22221f0a-e6f8-5976-bf6c-1024268816e0","slug":"oxygen","fullItemName":"Oxygen"},{"id":"25b01dc5-45e8-563d-872f-cfec63e33029","slug":"opioids","fullItemName":"Opioids"},{"id":"b7f561a2-0802-545a-b7d1-db218387a6e5","slug":"benzodiazepines","fullItemName":"Benzodiazepines"}]},{"id":"9f0bdd3b-82e3-5cbb-908f-d36a887457a8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5c3c7cfe-04b9-5ac4-9255-be56a20c7b5c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3aa322d7-2279-512c-93a7-55426d21da21","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b889ecee-814d-5e79-b596-a024fbee0acf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7e27fb69-52fd-5ddc-8f84-6164bb8615d0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c1800f44-6de2-534a-a4ff-32b8b5cf6e24","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6b7633c0-45a5-5a2e-b564-f185c2b9ef5f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2d28faa0-4a5f-565b-a431-6339d01f6e91","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ea721a0d-cda2-5620-8e3f-61e76920b9b3","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"dd2a2088-ea03-524a-9afd-6e0326949797","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field be770294-c952-4aba-b2ed-979f8855d708 --><h3>Previous changes</h3><!-- end field be770294-c952-4aba-b2ed-979f8855d708 -->","summary":null,"htmlStringContent":"<!-- begin item e27cc3f1-323b-4ee2-8c42-964c2d0f474a --><!-- begin field 19439bf2-49f8-4c7e-98a1-3a01b49f878b --><p><strong>July 2015 </strong>— topic title changed to reflect broader topic coverage than specifically cancer care.</p><p><strong>April 2015 </strong>—<strong> </strong>minor update. Update to the text to reflect a new law on drugs and impaired driving.</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>November 2012</strong> —<strong> </strong>reviewed. A literature search was conducted in August 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. Changes have been made to the section on when to offer a benzodiazepine. The section on prescribing oral opioids has been updated. A new prescribing information section on the use of subcutaneous opioids has been added.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators have been added to this topic. Issued in June 2011.</p><p><strong>February 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>April to August 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Changes have been made to the sections discussing the use of corticosteroids to treat dyspnoea (including emergency treatment). In the section on symptomatic treatment, more details on oxygen treatment and information about bronchodilators have been added. The topic has been restructured to include assessment of a person with dyspnoea in a palliative care situation, symptomatic treatment of dyspnoea in a palliative care situation, and treatment of dyspnoea of known cause in a palliative care situation.</p><p><strong>January 2006 </strong>— minor update. Prescriptions for diamorphine updated to reflect the change in handwriting requirements for controlled drug prescriptions. Issued in February 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>August 2003 </strong>— written. Validated in December 2003, and issued in February 2004.</p><!-- end field 19439bf2-49f8-4c7e-98a1-3a01b49f878b --><!-- end item e27cc3f1-323b-4ee2-8c42-964c2d0f474a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}